It has been a rough year for shareholders of CSL Ltd (ASX: CSL).
Earlier this week, the biotech giant’s share price hit a multi-year low of $140.93 during a broader market selloff.
Even after a modest rebound, the stock is still trading at $142.58, which leaves it down roughly 43% over the past 12 months.
For a company long considered one of the highest-quality businesses on the ASX, that sort of decline naturally raises questions. What exactly has gone wrong, and does the weakness create an opportunity for investors?
Image source: Getty Images
A combination of issues weighing on sentiment and the CSL share price
Part of the explanation comes down to the company’s recent performance.
CSL’s latest half-year results were softer than…
